Table 1.

CRs, oxidative stress, inflammation and Melatonin in PD.

	Factors	Targets	Models	References
CRs in PD	Per2	D2 dopaminergic receptor	Rat dorsal striatum	[42]
	Clock/Bmal1	D2 dopaminergic receptor	D2R knockout mice	[43]
	Per, Bmal1	D2 receptor agonist quinpirole	Mouse striatum	[44]
	Diurnal motor variation	Levodopa therapy	PD patients	[48]
	Heart rate variability	Diurnal and frequency low	PD patients	[51]
	Bmal1, Per, Rev-Erb	Augmentation of sleep latency, diminution of sleep efficacy and diminution of rapid eye movement sleep	PD patients	[52]
	Per, Cry, Bmal1	Diminution of serotonin metabolism, diminution of melatonin	RIPD male wistar rat	[53]
	Bmal1	DA system, 6-OHDA blunt period	Dorsal striatum rat	[56]
	Bmal1	Pittsburgh sleep quality index score	PD patients	[57]
Inflammation in PD	HLA-DR-positive reactive microglia	Diminution of cortical choline acetyltransferase activity	PD patients	[59]
	TNF alpha	Augmentation of caspase 1 and 3	PD patients	[60]
	CXCR4	Augmentation of microglia activity	Post-mortem PD patients	[61]
	LRRK2	IFN gamma response	PD patients	[62]
	LRRK2	IL-1, Cox2, NF-kappaB augmentation	Microglia cells	[63]
	LRRK2	TNF alpha, NF-kappaB augmentation	PD patients	[64]
CRs and inflammation in PD	Bmal1	Ly6C(hi) inflammatory monocyte	Monocytes	[65]
	Rev-Erb	IL-6	Patient inflammatory diseases	[66]
	Clock	Histone acetyltransferase	Clock-out cells	[67]
	Clock/Bmal1	NF-kappaB	Mouse model	[68]
	Rev-Erb	Ccl2 expression	C57BL/6J mice	[69]
	Rev-Erb	TH17	Nfil3(−/−) mice	[70]
	ROR	IL-1beta, IL-6	Wild type and staggerer (RORalpha(sg/sg)) mice	[71]
	Cry	TNF-alpha, IL-1beta, IL-6	Cry1(−/−)Cry2(−/−) mice	[72]
Melatonin in PD	Melatonin	Mitochondrial complex 1 activity	Hcy rat model of PD	[73]
	Melatonin	GSH levels	Rat model of PD	[74]
	Melatonin	6-OHDA levels	Hemiparkinsonian rat model	[75]
	Melatonin	GSH levels, SOD levels	Hemiparkinsonian rat model	[76]
	Melatonin	mRNAs of antioxidants	PC12 cells	[77]
	Melatonin	Apoptosis, necrosis	PC12 cells	[78]
	Melatonin	Caspase 3/7	PC12 cells	[79]